Analysts Weigh Up Benefits Of Big Bayer Restructuring
Analysts Weigh Up Benefits Of Big Bayer Restructuring
$131.00
The recent shakeup at Bayer AG took some observers by surprise, but was heralded by most as a much-needed measure to maintain the German giant’s viability. Find out how this restructuring will play out, and what top analysts make of the move to streamline the organization.
Publisher: Scrip
- Description
Just prior to Bayer AG’s capital market day in London in December 2018, the pharma giant surprised some with an announcement that the company was planning a major restructuring. Find out the details of the various measures this streamlining process will take, the rationale behind some of the moves being made, including its exit from the animal health market, the projected cost-savings it’s expected to produce, and how analysts are reacting to the plans in this informative article from Scrip.
© Pharma Intelligence UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
What’s Under The Iceberg: GE Healthcare’s Deep Dive Look At Future Of Gene... 
Sign up to the